Pharmacokinetic-pharmacodynamic analysis of lopinavir-ritonavir in combination with efavirenz and two nucleoside reverse transcriptase inhibitors in extensively pretreated human immunodeficiency virus-infected patients

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 1, 2003, Pages 350-359

  Hsu, Ann ^a   Isaacson, Jeffrey ^a   Brun, Scott ^a   Bernstein, Barry ^a   Lam, Wayne ^a   Bertz, Richard ^a   Foit, Cheryl ^a   Rynkiewicz, Karen ^a   Richards, Bruce ^a   King, Martin ^a   Rode, Richard ^a   Kempf, Dale J ^a   Granneman, G Richard ^a   Sun, Eugene ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS INFECTION;

EID: 12244262297     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.1.350-359.2003     Document Type: Article

References (45)

1. Acosta, E. P., K. Henry, L. Baken, L. M. Page, and C. V. Fletcher. 1999. Indinavir concentrations and antiviral effect. Pharmacotherapy 19:708-712.
2. Benson, C. A., S. Deeks, S. C. Brun, R. Gulick, J. J. Eron, H. A. Kessler, R. L. Murphy, C. Hicks, M. King, D. Wheeler, J. Feinberg, R. Stryker, P. Sax, S. Riddler, M. Thompson, K. Real, A. Hsu, D. Kempf, A. Japour, and E. Sun. 2002. 48-Week safety and antiviral activity of lopinavir/ritonavir plus nevirapine and two nucleoside analogs in human immunodeficiency virus protease inhibitor-experienced patients. J. Infect. Dis. 185:599-607.
3. Hicks, C., S. Brun, M. King, T. Marsh, S. Deeks, C. Benson, R. Gulick, H. Kessler, R. Murphy, D. Wheeler, J. Feinberg, J. Eron, R. Sax, R. Stryker, S. Riddler, M. Thompson, D. Kempf, A. Japour, and E. Sun. 2001. Kaletra (lopinavir/ritonavir) therapy in single protease inhibitor experienced patients: 144-week follow-up. Eighth European Conference on Clinical Aspects and Treatment of HIV Infection, Athens, Greece.
4. Bertz, R., C. Renz, C. Foit, J. Swerdlow, X. Ye, O. Jasinsky, A. Hsu, G. R. Granneman, and E. Sun. 2001. Steady-state pharmacokinetics of Kaletra (lopinavir/ritonavir 400/100 mg BID) in HIV-infected subjects when taken with food. Second International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands.
5. Bertz, R., W. Lam, A. Hsu, G. R. Granneman, and E. Sun. 2001. Effects of gender, race, age and weight on the pharmacokinetics of lopinavir after single-dose Kaletra. Second International Workshop on Clinical Pharmacology of HIV Therapy, Noordwijk, The Netherlands.
6. Burger, D. M., P. W. H. Hugen, J. M. Prins, M. E. van de Ende, P. Reiss, and J. M. A. Lange. 1999. Pharmacokinetics of an indinavir/ritonavir 800/100 mg BID regimen. Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, III.
7. Burger, D. M., R. Hoetelmans, P. Hugen, J. Mulder, P. Meenhorst, P. Koopmans, K. Brinkman, M. Keuter, W. Dolmans, and Y. Hekster. 1998. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antiviral Ther. 3:215-220.
8. Cahn, P., C. Renz, X. Saez-Llorens, A. Violari, P. Gomez, and E. Sun. 2001. Treatment of HIV-infected children with Kaletra (lopinavir/ritonavir) oral solution: 60-week follow up. First LAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina.
9. Cameron, D. W., A. J. Japour, Y. Xu, A. Hsu, C. Cohen, C. Farthing, S. Follansbee, M. Markowitz, J. Mellors, D. Poretz, J. Angel, D. Ho, D. McMahon, V. Devanarayan, R. Rode, M. Salgo, D. J. Kempf, R. G. Granneman, J. M. Leonard, and E. Sun. 1999. Ritonavir and saquinavir combination therapy for the treatment of HIV infection. AIDS 13:213-224.
10. Casado, J. L., M. J. Perez-Elias, A. Antela, R. Sabido, P. Marti-Belda, F. Dronda, J. Blazquez, and C. Quereda. 1998. Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patients. AIDS 12:F131-F135.
11. Clevenbergh, P., J. Durant, P. Halfon, P. del Giudice, V. Mondain, N. Montagne, J. M. Schapiro, C. A. B. Boucher, and P. Dellamonica. 2000. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt study: week 48 follow-up. Antiviral Ther. 5:65-70.
12. Clumeck, N., S. Brun, J. Sylte, J. Isaacson, S. Chen, A Lazzarin, P. M. Girard, J. Rockstroh, S. Becker, G. Pantaleo, F. Bergmann, S. Danner, D. Ho, R. Tubiana, G. Carosi, R. Bertz, A. Hsu, B. Richards, M. King, D. Kempf, and E. Sun. 2001. Kaletra (ABT-378/ritonavir) and efavirenz: 48-week safety/efficacy/pharmaco kinetic evaluation in multiple PI-experienced patients. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, III.
13. Deeks, S. G., N. S. Hellmann, R. M. Grant, N. T. Parkin, C. J. Petropoulos, M. Becker, W. Symonds, M. Chesney, and P. A. Volberding. 1999. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type I protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J. Infect. Dis. 179:1375-1381.
14. Deeks, S. G., R. M. Grant, G. W. Beatty, C. Horton, J. Detmer, and S. Eastman. 1998. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 12: F97-F102.
15. DeGruttola, V., L. Dix, R. D'Aquila, D. Holder, A. Phillips, M. Ait-Khaled, J. Baxter, P. Clevenbergh, S. Hammer, R. Harrigan, D. Katzenstein, R. Lanier, M. Miller, M. Para, S. Yerly, A. Zolopa, J. Murray, A. Patick, V. Miller, S. Castillo, L. Pedneault, and J. Mellors. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: reanalysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Ther. 5:41-48.
16. Durant, J., P. Clevenbergh, R. Garraffo, P. Halfon, S. Icard, P. Del Giudice, N. Montagne, J. M. Schapiro, and P. Dellamonica. 2000. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: pharmacological data from the Viradapt study. AIDS 14:1333-1339.
17. Ellner, P. D., and H. Neu. 1981. The inhibitory quotient: a method for interpreting minimum inhibitory concentration data. JAMA 246:1575-1578.
18. Erb, P., M. Battegay, W. Zimmerli, M. Rickenbach, M. Egger, et al. 2000. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Arch. Intern. Med. 160:1134-1140.
19. Gross, R., H. M. Friedman, W. B. Bilker, J. Coyne, and B. L. Strom. 2001. Adherence wanes after first month of HIV therapy. Clin. Pharmacol. Therap. 69:83.
20. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. McMahon, L. Jonas, A. Meibohm, D. Holder, W. A. Schleif, J. H. Condra, E. A. Emini, R. Isaacs, J. A. Chodakewitz, and D. D. Richman. 1998. Simultaneous versus sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. JAMA 280:35-41.
21. Hass, D. W., A. Eduardo, M. A. Thompson, R. de Jesus Pedro, J. Gallant, D. Uip, J. Currier, L. M. Noriega, D. S. Lewi, P. Uribe, J. Benetucci, P. Cahn, D. Paar, A. C. White, Jr., A. C. Collier, C. H. Ramirez-Ronda, C. Harvey, M. Chung, D. Mehrotra, J. Chodakewitz, and B.-Y. Nguyen. 2000. Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine. AIDS 14:1973-1978.
22. Ho, D. D., A. U. Neumann, A. S. Perelson, W. Chen, J. M. Leonard, and M. Markowitz. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373:123-126.
23. Hsu, A., R. Bertz, D. Hickman, M. Emery, G. Kumar, J. Dennison, S. Vasavabibda, A. Molla, D. Kempf, G. R. Granneman, and E. Sun. 2001. Assessment of plasma protein binding of lopinavir and ritonavir between in vitro and ex vivo experiments and between HIV-infected patients and HIV-negative healthy volunteers. Eighth Conference on Retroviruses and Opportunistic Infections, Chicago, III.
24. Hsu, A., D. Kempf, G. R. Granneman, and E. Sun. 2002. Exploring theoretical mechanisms for lack of resistance to lopinavir/ritonavir (Lopinavir/r) in antiretroviral (ARV)-naive subjects. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, Wash.
25. Hsu, A., G. R. Granneman, M. Heath-Chiozzi, C. Wong, L. Manning, R. Brooks, and E. Sun. 1998. Indinavir can be given with regular meals when taken with ritonavir. Twelfth World Congress on AIDS, Geneva, Switzerland.
26. Kakuda, T. N., L. M. Page, P. L. Anderson, K. Henry, T. W. Schacker, F. S. Rhame, E. P. Acosta, R. C. Brundage, and C. V. Fletcher. 2001. Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrob. Agents Chemother. 45:236-242.
27. Kempf, D., S. Brun, R. Rode, J. Isaacson, M. King, Y. Xu, K. Real, A. Hsu, G. R. Granneman, Y. Lie, N. Hellman, B. Bernstein, and E. Sun. 2000. Identification of clinically relevant phenotypic and genotypic breakpoints for ABT-378/r in multiple PI-experienced, NNRTI-naive patients. Fourth International Workshop on HIV Drug Resistance and Treatment Strategies Conference, Sitges, Spain.
28. Kempf, D., J. Isaacson, M. King, S. C. Brun, Y. Xu, K. Real, B. M. Bernstein, A. J. Japour, E. Sun, and R. A. Rode. 2001. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among viral isolates from protease inhibitor-experienced patients. J. Virol. 75:7462-7469.
29. a. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, J. Sylte, B. Richards, B. Bernstein, R. Rode, and E. Sun. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease-inhibitor-experienced HIV-1 infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7:165-174.
30. Kempf, D. J., K. C. Marsh, G. Kumar, A. D. Rodrigues, J. F. Denissen, E. McDonald, M. J. Kukulka, A. Hsu, G. R. Granneman, P. A. Baroldi, E. Sun, D. Pizzuti, J. J. Plattner, D. W. Norbeck, and J. M. Leonard. 1997. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob. Agents Chemother. 41:654-660.
31. Kumar, G. N., A. D. Rodrigues, A. M. Buko, and J. F. Denissen. 1996. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J. Pharmacol. Exp. Ther. 277:423-431.
32. Kumar, G. N., J. Dykstra, E. M. Roberts, V. K. Jayanti, D. Hickman, J. Uchic, Y. Yao, B. Surber, S. Thomas, and G. R. Granneman. 1999. Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab. Dispos. 27:902-908.
33. Nascimbeni, M., C. Lamotte, G. Peytavin, R. Farinotti, and F. Clavel. 1999. Kinetics of antiviral activity and intracellular pharmacokinetics of human immunodeficiency virus type 1 protease inhibitors in tissue culture. Antimicrob. Agents Chemother. 43:2629-2634.
34. Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H.-M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. B. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766.
35. Molla, A., S. Vasavanonda, G. Kumar, H. L. Sham, M. Johnson, B. Grabowski, J. F. Denissen, W. Kohlbrenner, J. J. Plattner, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1998. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology 250:255-262.
36. Murphy, R. L., S. Brun, C. Hicks, J. T. Eron, R. Gulick, M. King, A. C. White, C. Benson, M. Thompson, H. A. Kessler, S. Hammer, R. Bertz, A. Hsu, A. Japour, and E. Sun. 2001. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 15:F1-F9.
37. Palella, F. J., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
38. Para, M. F., D. V. Glidden, R. W. Coombs, A. C. Collier, J. H. Condra, C. Craig, R. Bassett, R. Leavitt, S. Snyder, V. McAuliffe, and C. Boucher. 2000. Baseline human immunodeficiency virus type 1 phenotype, genotype, and RNA response after switching from long-term hard-capsule saquinavir to indinavir or soft-gel-capsule saquinavir in AIDS Clinical Trials Group protocol 333. J. Infect. Dis. 182:733-743.
39. Paterson, D. L., S. Swindells, J. Mohr, M. Brester, E. N. Vergis, C. Squire, M. M. Wagener, and N. Singh. 2001. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133:21-30.
40. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
41. Piketty, C., E. Race, P. Castiel, L. Belec, G. Peytavin, A. Si-Mohamed, G. Gonzalez-Canali, L. Weiss, F. Clavel, and M. D. Kazatchkine. 1999. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS 13:F71-F77.
42. Ruane, P., J. Mendonca, A. Timerman, P. Cernohous, E. Bauer, B. Bernstein, and E. Sun. 2001. Kaletra versus nelfinavir in antiretroviral-naive subjects: week 60 comparison in a phase III, blinded, randomized clinical trial. First IAS Conference on HIV Pathogenesis and Treatment, Buenos Aires, Argentina.
43. + T-cell counts in HIV infected patients. Ann. Intern. Med. 124:1039-1050.
44. Sham, H. L., D. J. Kempf, A. Molla, K. C. Marsh, G. N. Kumar, C.-M. Chen, W. Kati, K. Stewart, R. Lal, A. Hsu, D. Betebenner, M. Korneyeva, S. Vasavanonda, E. McDonald, A. Saldivar, N. Wideburg, X. Chen, P. Niu, C. Park, V. Jayanti, B. Grabowski, G. R. Granneman, E. Sun, A. J. Japour, J. M. Leonard, J. J. Plattner, and D. W. Norbeck. 1998. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob. Agents Chemother. 42:3218-3224.
45. Shulman, N., A. R. Zolopa, D. Havlir, A. Hsu, C. Renz, S. Boller, P. Jiang, R. Rode, J. Gallant, E. Race, D. J. Kempf, and E. Sun. Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in HIV-infected patients with ongoing viremia. Antimicrob. Agents Chemother., in press.